The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis
Year: 2025
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Background: Recent studies have reported the excellent diagnostic performance of fibroblast-activated protein inhibitor (FAPI) positron emission tomography (PET) in patients with digestive system tumors. We performed a systematic review and meta-analysis to investigate the impact of FAPI PET on staging and management changes in those patients and to further elucidate the important role of FAPI PET in clinical practice. Methods: A thorough literature search was performed in PubMed, EMBASE, MEDLINE, and Scopus databases until May 31, 2024, for eligible studies regarding the impact of FAPI PET on staging and management in patients with digestive system tumors. Quality assessment was performed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and QUADAS-comparative (QUADAS-C). The proportions of changes were pooled using a random- or fixed-effect model according to the heterogeneity. Sub-group analyses were utilized to explore heterogeneity. Results: =0%) in restaging group. Relative proportions of major and minor management change were 34.9% (45/129) and 41.9% (54/129), respectively. Conclusions: FAPI PET can significantly alter the staging and management plan in patients with digestive system tumors. Further prospective studies are warranted to evaluate the impact of FAPI PET on staging and management changes for certain types of cancer.
Institutions: Sichuan University, West China Hospital of Sichuan University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7117744666